Elanco Animal Health Inc (NYSE: ELAN) shares surged 5.24% in pre-market trading on Wednesday following the company's announcement of better-than-expected first-quarter results and an increase in its full-year revenue guidance.
The animal health company reported first-quarter adjusted earnings of $0.37 per share, significantly beating the analyst consensus estimate of $0.31. This represents a 19.35% surprise to the upside and an 8.82% increase from the same period last year. Quarterly revenue came in at $1.19 billion, surpassing the analyst estimate of $1.17 billion by 2.11%. The strong performance was driven by organic growth and operational efficiencies.
In light of the robust results, Elanco raised its 2025 revenue guidance to a range of $4.51 billion to $4.58 billion, up from the previous forecast of $4.45 billion to $4.51 billion. The company also increased its 2025 innovation revenue target to $660 million to $740 million, signaling confidence in its product pipeline. Despite headwinds from tariffs and foreign exchange rates, Elanco maintained its full-year adjusted earnings guidance of $0.80 to $0.86 per share, demonstrating the company's ability to navigate challenges while delivering growth.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.